Traveler’s Diarrhea Pipeline Market Insights Report 2022 Featuring Key Players – Nippon Shinyaku, Immuron, Eveliqure Biotechnologies, Lumen Bioscience, Scandinavian Biopharma, & Sigmoid Pharma – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Traveler’s Diarrhea – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “Traveler’s Diarrhea- Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler’s Diarrhea pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

“Traveler’s Diarrhea- Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s Diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s Diarrhea commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

The companies and academics are working to assess challenges and seek opportunities that could influence Traveler’s Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler’s Diarrhea.

Traveler’s Diarrhea Emerging Drugs Chapters

This segment of the Traveler’s Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Traveler’s Diarrhea Emerging Drugs

IMM124E:Immuron

IMM-124E is a first-in class, oral polyclonal antibody therapy developed to target the endotoxin lipopolysaccharide (LPS) and other pathogenic bacterial components in the human gastrointestinal tract reducing LPS-related inflammation and systemic translocation. The drug is in Phase III clinical studies for the treatment of Traveler’s diarrhea in individuals traveling to endemic areas for ETEC exposure.

LMN101: Lumen Bioscience

LMN-101 is a cocktail of neutralizing monoclonal antibody-like protein biologics designed to bind and neutralize the primary causes of traveler’s diarrhea: the bacterial pathogens Campylobacter jejuni and enterotoxigenic E. coli. The drug is in Phase II clinical studies for the treatment of Traveler’s diarrhea.

Traveler’s Diarrhea: Therapeutic Assessment

This segment of the report provides insights about the different Traveler’s Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Traveler’s Diarrhea

There are approx. 6+ key companies which are developing the therapies for Traveler’s Diarrhea. The companies which have their Traveler’s Diarrhea drug candidates in the most advanced stage, i.e. Phase III include, Immuron.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Traveler’s Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Traveler’s Diarrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Traveler’s Diarrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s Diarrhea drugs.

Traveler’s Diarrhea Report Insights

• Traveler’s Diarrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Traveler’s Diarrhea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Nippon Shinyaku
• Immuron
• Eveliqure Biotechnologies
• Lumen Bioscience
• Scandinavian Biopharma
• Sigmoid Pharma Limited

Key Products

• Prulifloxacin
• IMM 124E
• Campylobacter jejuni/Escherichia coli oral vaccine
• Escherichia coli/Shigella oral vaccine
• LMN-101
• Traveller’s diarrhoea vaccine
• Oral vaccines

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/jog835

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900